Millennium Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Millennium Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-135,500	Closed	-$757K	–	7912
2022 Q1	$757K	Buy	+135,500	New	+$558K	﹤0.01%	4784
2021 Q3	–	Sell	-67,700	Closed	-$446K	–	7658
2021 Q2	$446K	Buy	67,700 +37,700	+126%	+$260K	﹤0.01%	5405
2021 Q1	$220K	Buy	+30,000	New	+$259K	﹤0.01%	5445
2018 Q3	–	Sell	-95,950	Closed	-$2.17M	–	4479
2018 Q2	$2.17M	Sell	95,950 -5,460	-5%	-$129K	﹤0.01%	2341
2018 Q1	$2.94M	Buy	101,410 +72,360	+249%	+$2.12M	﹤0.01%	2117
2017 Q4	$810K	Buy	29,050 +10	+0%	+$310	﹤0.01%	2823
2017 Q3	$1.06M	Hold	29,040	–	–	﹤0.01%	2483
2017 Q2	$645K	Buy	+29,040	New	+$229K	﹤0.01%	2679

Millennium Management's AVEO Position: Q1 2023 in Review

Millennium Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 49,299 shares — an estimated $737K sold.

Millennium Management first reported a position in AVEO in Q2 2013 and held it in 27 quarters. The position peaked at $12.1M in Q1 2018. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

Millennium Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 49,299 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $737K.
Millennium Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 27 quarters.
Millennium Management's AVEO Pharmaceuticals, Inc. position peaked at $12.1M in Q1 2018.
0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.